Clinical Trial Update: Efficacy of Belatacept in Reducing DSA [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating belatacept for reducing donor-specific antibodies in kidney transplant recipients is completed, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplantation

Drugs mentioned

• belatacept (belatacept)

Snippet

Sponsor: East Carolina University | Conditions: Kidney Transplantation | Phase 4 | Status: COMPLETED | Results posted: 2017-07-06